Thymidine Kinase 2 Deficiency (TK2d): European Commission approves doxecitine and doxribtimine (KYGEVVI®) as first and only treatment
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that the European Commission (EC) has granted marketing authorization under exceptional circumstances for KYGEVVI (doxecitine and doxribtimine) for the treatment…